Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Lessons Learned From Lockdown: Viral Hepatitis–Related Liver Disease in the COVID-19 Era
  • CME
  • CE

Robert G. Gish, MD
Released: January 10, 2022
Back Next


  1. CEVHAP. Viral hepatitis. Fast facts. cevhap.org. Accessed December 29, 2021.
  2. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021: towards ending viral hepatitis. Geneva: World Health Organization; 2016.
  3. Center for Systems Science and Engineering at Johns Hopkins University. COVID-19 dashboard. coronavirus.jhu.edu/map.html. Accessed December 29, 2021.
  4. Blach S, Kondili LA, Aghemo A, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74:31-36.
  5. Wang Q, Davis PB, Xu R. COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States. EClinicalMedicine. 2021;31:100688.
  6. Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74:567-577.
  7. Li Y, Regan J, Fajnzylber J, et al. Liver fibrosis index FIB-4 is associated with mortality in COVID-19. Hepatol Commun. 2021;5:434-445.
  8. Webb G, Marjot T, Cook J, et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol. 2020;5:P1008-1016.
  9. Rabiee A, Sadowski B, Adeniji N, et al. Liver injury in liver transplant recipients with coronavirus disease 2019 (COVID-19): U.S. multicenter experience. Hepatology. 2020;72:1900-1911.
  10. Colmenero J, Rodriguez-Peralvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021;74:148-155.
  11. Saviano A, Wrensch F, Ghany M, Baumert T. Liver disease and coronavirus disease 2019: from pathogenesis to clinical care. Hepatology. 2021;74:1088-1100.
  12. American Association for the Study of Liver Diseases. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. aasld.org/about-aasld/covid-19-and-liver#consensus-statement. Accessed December 29, 2021.
  13. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals. fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised. Accessed December 29, 2021.
  14. Centers for Disease Control and Prevention. CDC expands eligibility for COVID-19 booster shots to all adults. cdc.gov/media/releases/2021/s1119-booster-shots.html. Accessed December 29, 2021.
  15. Boyarsky B, Ou M, Greenberg R, et al. Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients. Transplantation. 2021;105:e56-e57.
  16. Boyarsky B, Werbel W, Avery R, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients JAMA. 2021;325:1784-1786.
  17. Boyarsky B, Werbel W, Avery R, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325:2204-2206.
  18. American Association for the Study of Liver Diseases. AASLD expert panel consensus statement: vaccines to prevent COVID-19 in patients with liver disease. aasld.org/sites/default/files/2021-08/AASLD%20COVID-19%20Vaccine%20Document%20Update%208.30.2021.pdf. Accessed December 29, 2021.
  19. Nouri S, Khoong E, Lyles C, et al. Addressing equity in telemedicine for chronic disease management during the COVID-19 pandemic. catalyst.nejm.org/doi/full/10.1056/CAT.20.0123. Accessed December 29, 2021.
  20. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infections by primary care providers. N Engl J Med. 2011;364:2199-2207.
  21. Project ECHO. How ECHO is making a difference. hsc.unm.edu/echo. Accessed December 29, 2021. 
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grants provided by:
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings